SynOx Therapeutics Limited
SynOx Therapeutics is a late-stage clinical biopharmaceutical company developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of Tenosynovial Giant Cell Tumour (TGCT) and other macrophage-driven disorders. The company focuses on providing effective therapies for rare and debilitating diseases with a focus on improving patient quality of life. Emactuzumab has shown significant clinical activity in earlier trials.
Funding Round: Series B
Funding Amount: $75M
Date: 22-Apr-2024
Investors: Forbion, HealthCap, Bioqube Ventures
Markets: Biopharmaceutical, Oncology, Biotechnology
HQ: Dublin, County Dublin, Ireland
Founded: 2020
Website: https://synoxtherapeutics.com/
LinkedIn: https://ie.linkedin.com/company/synox-therapeutics
Facebook: https://www.facebook.com/SynOxTherapeutics
Crunchbase: https://www.crunchbase.com/organization/synox-therapeutics
Leave a Comment
Comments
No comments yet.